Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

September 4, 2024

Study Completion Date

September 4, 2025

Conditions

NSCLC

Interventions

DRUG

Cadonilimab

Cadonilimab + chemotherapy

Trial Locations (2)

RECRUITING

NINGBO No.2 Hospital, Ningbo

NOT_YET_RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER